Objectives We sought to evaluate the utility of the JOSTENT polytetrafluoroethylene (PTFE) stentgraft (Jomed GmbH, Rangendingen, Germany) in patients with diseased saphenous vein grafts (SVGs) undergoing percutaneous coronary intervention (PCI).
As many as 25% to 30% of saphenous vein grafts (SVGs) fail within 12 to 18 months after coronary artery bypass graft surgery (CABG) (1), a proportion that increases to Ͼ50% beyond 10 years (2, 3) . Compared with treatment of native coronary arteries, percutaneous coronary intervention (PCI) of diseased SVGs is associated with higher rates of periprocedural complications and an increased incidence of clinical and angiographic restenosis (4, 5) . Distal protection devices improve the procedural safety of PCI in SVGs (6,7), whereas bare-metal stents (BMS) improve event-free survival compared with balloon angioplasty (8) . Recently, 2 small randomized trials have provided conflicting results as to whether drug-eluting stents (DES) further improve outcomes after PCI of SVGs (9, 10) . Novel approaches are needed to further improve the prognosis of diseased SVGs.
The JOSTENT stent-graft (Jomed GmbH, Rangendingen, Germany) consists of a distensible polytetrafluoroethylene (PTFE) membrane sandwiched between 2 316L stainless steel slotted tube, balloon-expandable stents ( Fig. 1) (11) . This device is currently available in the U.S. as the GraftMaster (Abbott Vascular, Santa Clara, California) under a Humanitarian Device Exemption for treatment of life-threatening coronary perforations (12) . Hypothetical benefits of elective use of the JOSTENT PTFE stent-graft in SVGs include reduced periprocedural myocardial infarction (MI) (by trapping potentially embolic degenerated atherosclerotic debris behind the PTFE membrane) and decreased restenosis (by serving as a barrier isolating the lumen from smooth muscle cell proliferation, migration, and extracellular matrix production arising from the media) (13) . After favorable results from a multicenter registry (14) , 2 trials were performed in which the JOSTENT was randomized to BMS in diseased SVGs, demonstrating comparable or increased rates of MI, restenosis, and late occlusion with the stent-graft (15, 16) . However, neither of these trials mandated high-pressure balloon inflation or prolonged dual antiplatelet therapy, measures that might be necessary to mechanically optimize the implant and facilitate endothelialization without thrombosis. Moreover, follow-up was limited to only 6 and 12 months in these studies, precluding the opportunity to determine whether there are late benefits (or harm) from this device-a salient issue, because the time course of both target lesion revascularization (TLR) and target vessel revascularization (TVR) might be protracted in SVGs compared with native coronary arteries (17) .
Therefore, we performed a prospective, multicenter, randomized, controlled trial termed BARRICADE (Barrier Approach to Restenosis: Restrict Intima to Curtail Adverse Events) to evaluate the utility of the JOSTENT PTFE stent-graft for the treatment of discrete atherosclerotic lesions in diseased SVGs. JOSTENT post-dilation to Ն18 atm was mandated to overcome limitations of prior studies, as was use of dual antiplatelet therapy for Ն8 months, and all patients were followed for a total duration of 5 years. The present report represents the principal and final analysis from the BARRICADE trial.
Methods
Enrollment criteria. To be eligible for the BARRICADE trial, patients Ն18 years of age with clinical evidence of ischemia or a positive functional study had to have 1 or 2 SVG lesions eligible for PCI with either both lesions in 1 SVG or 1 lesion in each of 2 SVGs. Lesion eligibility required all the following to be present: visually estimated diameter stenosis of Ն50% and Ͻ100%; target vessel diameter Ն3.0 mm and Յ5.0 mm; lesion length Յ25 mm; and Thrombolysis In Myocardial Infarction flow grade Ն1 after successful wire passage. All patients had to agree to all follow-up procedures and provide informed, written consent. Patients were excluded from randomization if any of the following were present: contraindication to aspirin, heparin, clopidogrel, stainless steel, PTFE, or contrast media that could not be adequately pre-medicated; MI within 24 h before the procedure or any creatine phosphokinase (CPK)-myocardial band (MB) greater than normal; left ventricular ejection fraction Ͻ25%; PCI in a nonstudy vessel required Յ24 h before or during the index procedure or after (if staged procedure earlier, all other entry criteria must be met, including normal baseline creatine kinase-MB); unprotected left main disease; target lesion involving the distal anastomosis; presence of a Ն50% untreated stenosis proximal or distal to the target lesion; stent(s) located within 5 mm of the target lesion borders; excessive proximal tortuosity or lesion angulation; current participation in another investigational drug or device trial that had not completed the entire follow-up period; comorbidity with anticipated life expectancy to Յ12 months; liver function tests Ͼ3ϫ normal; serum creatinine Ն2.0 mg/dl; platelet count Ͻ100,000 cells/mm 3 ; hemoglobin Ͻ10.0 g/dl; history of stroke or transient ischemic attack within 6 months; gastrointestinal bleeding within 6 months; history of bleeding diathesis or coagulopathy or will refuse blood transfusions; and active pregnancy or lactation. Protocol and randomization. Direct stenting without predilation was not permitted. Before randomization, treatment with any U.S. Food and Drug Administrationapproved distal protection and/or thrombectomy device was permitted at the discretion of the operator, followed by pre-dilation with an undersized balloon catheter. If all eligibility criteria were present after pre-dilation, patients were randomized 1:1 in open-label fashion to the JOSTENT versus any U.S. Food and Drug Administration-approved BMS. Randomization was performed in random blocks of 4 to 6, stratified by the prior use of distal protection and/or thrombectomy. For patients randomized to the JOSTENT, the device was implanted at a nominal pressure, after which post-dilation with a noncompliant balloon was mandatory at a 1 to 1.1:1 balloon/artery ratio, to Ն18 atm. The JOSTENT was pre-mounted and available in lengths ranging from 9 to 29 mm and in diameters ranging from 3.0 to 5.0 mm. Only 1 JOSTENT was intended for a single lesion, by intent; however, additional JOSTENTs were permitted as necessary to treat residual diseased segments or edge dissections. The BMS were implanted according to standard of care.
Before the procedure patients received aspirin Ն325 mg, and clopidogrel 300 mg was recommended. Procedural anticoagulation was achieved with intravenous heparin, with the activated clotting time maintained at Ն300 s (200 to 250 s, if a glycoprotein IIb/IIIa inhibitor was used per investigator discretion). After the procedure all patients were administered aspirin 325 mg daily indefinitely. Patients who received a JOSTENT were administered clopidogrel 75 mg daily for at least 8 months, whereas clopidogrel was recommended for at least 1 month in patients treated with BMS. The CPK and CPK-MB levels were measured at baseline and every 8 h 3ϫ within 24 h after the procedure. An electrocardiogram was obtained at baseline, immediately after the procedure, at discharge, and additionally for any recurrent symptoms.
Clinical follow-up visits were planned at the time of discharge, 1 month, 8 months, 9 months, 12 months, and then yearly through 5 years. In addition, follow-up angiography was planned in all patients at 8 months after discharge, unless angiography performed before 8 months showed restenosis of the target lesion. Data management. Study monitors verified all case report forms data on-site. Major adverse cardiac events were adjudicated by an independent committee blinded to treatment allocation. Quantitative coronary angiography (QCA) analyses were performed at an independent core angiographic laboratory by technicians blinded to treatment assignment and clinical outcomes as previously described (18) . Intravascular ultrasound (IVUS) guidance was not required but, if performed, was analyzed at an independent core ultrasound laboratory. End points and definitions. The primary end point was the rate of binary angiographic restenosis in the target lesion at 8 months, defined as a Ͼ50% diameter stenosis within the stent or the 5-mm proximal or distal stent margins. The secondary end point was target vessel failure (TVF) at 9 months, defined as the composite of all-cause death, MI, or clinically driven TVR. Myocardial infarction was diagnosed by a rise of CPK-MB to Ͼ3ϫ normal. Target vessel revascularization was defined as repeat PCI or CABG of the target lesion (TLR) or vessel (TVR) containing the target lesion and was considered clinically driven if signs or symptoms of ischemia were present referable to the target vessel with an in-lesion diameter stenosis Ն50% by QCA or with an in-lesion diameter stenosis Ն70% by QCA in the absence of ischemia. Stent thrombosis was defined as thrombus or subacute closure within the stented vessel at the time of a clinically driven angiographic repeat study for documented ischemia or any death not attributed to a noncardiac cause within the first 30 days in the absence of documented angiographic stent patency. Sample size and statistical analysis. One hundred eightyfour patients/arm would provide 90% power to demonstrate superiority with a 2-sided ␣ ϭ 0.05, on the basis of published nonrandomized data with the JOSTENT (14)-assuming a binary restenosis rate at 8 months after BMS of 35% from the SAVED (Saphenous Vein De Novo) trial (8) and anticipating a reduction in restenosis to 20%. Two hundred fifty patients/ arm (500 total) were planned for enrollment, assuming an angiographic follow-up rate of 75%.
Categorical data were compared by chi-square or Fisher exact tests. Continuous data were expressed as mean Ϯ SD and compared by unpaired t tests. Lesion level The JOSTENT coronary stent graft (Jomed GmbH, Rangendingen, Germany) combines 2 laser-cut 316L slotted-tube balloon-expandable stainless steel stents with polytetrafluoroethylene graft material. The polytetrafluoroethylene material is wrapped around the inner stent (approximately 2.5ϫ) and sandwiched between the 2 stents. N S , V O L . 4 , N O . 3 , 2 0 1 1   M A R C H 2 0 1 1 : 3 0 0 -9 Stone et al. PTFE Stent-Graft Randomized Trial variables, whether continuous or categorical, were compared with Generalized Estimating Equations to accommodate correlated data. Adverse event analyses were performed with time-to-event data, are displayed with Kaplan-Meier methodology, and were compared with the log-rank test. All data are presented in the intent-to-treat population, consisting of all patients randomized, regardless of treatment actually received. A p value of 0.05 was required for statistical significance. Statistical analyses were performed by SAS (version 9.1, SAS, Cary, North Carolina). The baseline demographic and clinical characteristics were well matched between the 2 groups ( Table 1) . As shown in Table 2 , mean graft age was 10 years; 90% of lesions arose from the body of the SVG. Multiple SVG lesions were treated in 23% of patients. Distal protection devices were used in 43% of cases, and thrombectomy was rarely used. The maximal stent implantation pressure was significantly higher for the JOSTENT than for BMS. Aspirin use was high in both arms throughout the study. Thienopyridine use was more frequent in the JOSTENT group at 8-and 9-month follow-up (Table 1) . Angiographic results. The baseline angiographic measures in the 2 groups were well matched, except that the reference vessel diameter in the BMS group was slightly larger (Table 3 ). After PCI, the rates of Thrombolysis In Myocardial Infarction flow and angiographic complications were comparable in the 2 groups. At 8-month follow-up, late loss and the rates of binary restenosis and vessel occlusion were not statistically different between the JOSTENT and BMS groups ( Values are mean Ϯ SD or n (%).
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Stone et al. Clinical outcomes. After PCI, the peak CPK (106.2 Ϯ 107.1 IU/l vs. 91.9 Ϯ 79.3 IU/l, p ϭ 0.26) and CPK-MB levels (3.7 Ϯ 8.3 IU/l vs. 3.9 Ϯ 9.9 IU/l, p ϭ 0.84) were comparable in the JOSTENT and BMS groups, respectively. Similarly, there were no significant differences between groups in the rates of MI, stent thrombosis, or other adverse events at 30 days (Table 4) . At 9 months, the major secondary end point of TVF occurred in 32.2% of patients treated with the JOSTENT versus 22.1% of patients treated with BMS (hazard ratio: 1.54, 95% CI: 0.94 to 2.53, p ϭ 0.08). Significant differences between the 2 stents in the rates of any of the components of TVF at 9 months were not apparent (Table 4) . Table 5 shows the annual rates of adverse cardiovascular events between 1 and 5 years. Events continued to accrue in both arms over time but more so in the JOSTENT arm, such that by 2 years and beyond TVF occurred more frequently in patients assigned to the JOSTENT. At the end of the 5-year follow-up period, TVF had occurred in 68.3% of patients treated with the JOSTENT versus 51.8% of patients treated with BMS (hazard ratio: 95% CI: 1.59 1.13 to 2.23, p ϭ 0.007) (Fig. 2) . This difference was driven primarily by more rapidly increasing TLR rates in JOSTENT-treated patients. Although there were no statistically significant differences between the 2 stent types in the rates of MI or stent thrombosis, target vessel occlusion was noted more frequently in the JOSTENT arm during long-term follow-up.
Discussion
The present study was designed to overcome several potentially important limitations from prior randomized trials of the JOSTENT PTFE stent-graft in diseased SVGs. Notably, the JOSTENT-consisting of 2 balloon-expandable stents containing a PTFE membrane-is frequently underexpanded unless high-pressure inflations are performed (19) , which was not mandated in previous studies. Moreover, it has been hypothesized that delayed endothelialization of the PTFE material might explain the observed tendency toward thrombotic occlusion of the JOSTENT. Because prior studies required dual antiplatelet therapy for only 1 to 3 months (15,16), a more prolonged course might result in greater long-term graft patency. Finally, follow-up was truncated at 6 to 12 months in earlier trials (15, 16) , a duration insufficient to characterize the late prognosis after SVG intervention (17) .
In the present trial, high-pressure (Ն18 atm) inflations were performed in the JOSTENT with noncompliant balloons; dual antiplatelet therapy was prescribed for Ն8 months; and follow-up was continued for 5 years. Nonetheless, recruitment in the trial was terminated after enrollment of approximately 50% of the planned sample size for futility. The 8-month rates of late loss and restenosis were not superior to BMS (with high restenosis rates observed in both groups), even though angiog- Values are n (%) or mean Ϯ SD.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 4 , N O . 3 , 2 0 1 1 M A R C H 2 0 1 1 : 3 0 0 -9
Stone et al.
PTFE Stent-Graft Randomized Trial
raphy and IVUS demonstrated adequate stent expansion of the JOSTENT. Although IVUS was not performed at follow-up, these data suggest that either the porous PTFE membrane is not sufficiently restrictive to prevent neointimal hyperplasia from accumulating within the lumen or restenosis might also arise from circulating cellular mechanisms (20, 21) . Chronic recoil of the JOSTENT as an alternate mechanism in selected patients cannot be excluded without follow-up IVUS. Whether the trend toward increased late vessel occlusion with the JOSTENT is due to thrombosis or progressive hyperplasia also cannot be answered by this study, although it is clear that the 8-month use of dual antiplatelet therapy in most patients was insufficient to extend stent-graft patency. The present study is the first to systematically follow all patients for 5 years after SVG intervention. In this regard, long-term follow-up serves to emphasize the bleak prognosis that can be expected after PCI of diseased SVGs with either the JOSTENT or BMS. Five years after treatment with BMS, TVF occurred in more than one-half of all Values are n (%) or mean Ϯ SD.
PCI ϭ percutaneous coronary intervention; TIMI ϭ Thrombolysis In Myocardial Infarction. PTFE Stent-Graft Randomized Trial patients; MI, stent thrombosis, and vessel occlusion had occurred in 17.4%, 5.6%, and 7.8% of patients, respectively; TLR and TVR were required in 29.6% and 33.3% of patients, respectively; and 22.3% of patients had died. Five years after treatment with the JOSTENT, TVF had occurred in more than two-thirds of patients, with worse outcomes in every component measure compared with BMS. Use of the stent-graft also did not prevent acute angiographic complications such as distal embolization or periprocedural MI. Lower pressure inflations or less aggressive implantation technique might have prevented complications from the "toothpaste" effect but would likely have negatively affected late outcomes. Freedom from early thrombosis or late occlusion was not enhanced in a prior study by adding a heparin coat to the JOSTENT (22) . A different, totally encapsulated PTFE stent-graft has similarly failed to prevent periprocedural complications or late restenosis after SVG intervention (23) . Clearly, novel strategies are required for diseased SVGs. Registry studies have suggested that DES might be more efficacious than BMS (24, 25) , although the 2 small randomized trials that have been completed to date in this population were inconclusive (9, 10) . Doublestranded oligonucleotide E2F decoys to transcription factors implicated in the upregulation of several genes involved in neointimal hyperplasia have also failed to prolong SVG patency (26) . Pan-arterial CABG and hybrid PCI/CABG procedures should be increasingly employed to reduce the use of SVGs as bypass conduits. Study limitations. Recruitment was stopped early after a futility analysis. However, examination of the CIs around the final clinical and angiographic end points provides reassurance that a possible beneficial effect of the JOSTENT is unlikely to have been missed. IVUS guidance during the index procedure was used in a minority of patients, although it is uncertain whether acute procedural results would have been improved with IVUS, given the requirement to dilate all JOSTENTs to Ն18 atm with a noncompliant balloon. Only 76% of patients randomized to the JOSTENT were adherent with dual antiplatelet therapy at 8 months. It is doubtful that the results would have been meaningfully different had clopidogrel compliance been higher. Distal protection devices Event rates are Kaplan-Meier estimates (number of events). *Adjudicated as a cardiac death. †Each was adjudicated as a target lesion revascularization. were used in only 43% of enrolled patients, despite their documented ability to reduce periprocedural embolization and no reflow (6, 7) . This percentage, however, is higher than their contemporary use in SVG intervention. In this regard, although recruitment in this trial occurred more than 7 years ago, the tools for and technique of SVG PCI have not materially changed since then (other than the availability of DES). Finally, only SVGs with discrete (Յ25 mm long) lesions were enrolled in the present trial. The long-term outcomes in both arms would likely have been even worse had severely degenerated or occluded SVGs been included (27) . 
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